Agenus Dirección
Dirección controles de criterios 3/4
El CEO de Agenus es Garo Armen , nombrado en Jan 1994, tiene una permanencia de 32.33 años. compensación anual total es $1.35M, compuesta por 53% salario y 47% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.96% de las acciones de la empresa, por valor de $1.24M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 3.3 años, respectivamente.
Información clave
Garo Armen
Chief Executive Officer (CEO)
US$1.4m
Compensación total
| Porcentaje del salario del CEO | 52.97% |
| Permanencia del CEO | 32.3yrs |
| Participación del CEO | 1.0% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside
Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside
Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside
Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.
Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
BOT/BAL Trials And Cost Reductions Will Shape Future Advances
Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.Agenus: Novel Drugs That Just Are Not Novel
Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking AlphaThere's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...Agenus: 2024 May Finally Be The Year For A Major Turnaround
Summary Agenus is a beaten-down immuno-oncology biotech stock that has not participated in the recent biotech rally despite a promising pipeline and multiple partnerships. The company's lead asset, botensilimab (+/- balstilimab), has shown promising results in various advanced solid tumors (colorectal, pancreatic, melanoma, NSCLC, sarcomas, ovarian). A BLA is planned in mid-2024 for accelerated approval in metastatic colorectal cancer with potential for subsequent label expansion to earlier lines. Potential new partnerships are also being evaluated. Cash runway is a concern but planned transactions (sale of 2 assets and monetization of milestones/royalties from partnered programs) in 1H 2024 are expected to considerably extend cash runway. Considering AGEN's track record I am confident about these transactions. Read the full article on Seeking AlphaImproved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Agenus Inc.'s ( NASDAQ:AGEN ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a strong buy right now...News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Agenus Inc. ( NASDAQ:AGEN ) shareholders will have a reason to smile today, with the analysts making substantial...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$64m |
| Dec 31 2025 | US$1m | US$715k | -US$101k |
| Sep 30 2025 | n/a | n/a | -US$35m |
| Jun 30 2025 | n/a | n/a | -US$166m |
| Mar 31 2025 | n/a | n/a | -US$191m |
| Dec 31 2024 | US$4m | US$715k | -US$227m |
| Sep 30 2024 | n/a | n/a | -US$228m |
| Jun 30 2024 | n/a | n/a | -US$224m |
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$6m | US$710k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$263m |
| Mar 31 2023 | n/a | n/a | -US$240m |
| Dec 31 2022 | US$6m | US$689k | -US$220m |
| Sep 30 2022 | n/a | n/a | -US$215m |
| Jun 30 2022 | n/a | n/a | US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$10m | US$655k | -US$24m |
| Sep 30 2021 | n/a | n/a | US$4m |
| Jun 30 2021 | n/a | n/a | -US$226m |
| Mar 31 2021 | n/a | n/a | -US$190m |
| Dec 31 2020 | US$6m | US$677k | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$174m |
| Jun 30 2020 | n/a | n/a | -US$168m |
| Mar 31 2020 | n/a | n/a | -US$171m |
| Dec 31 2019 | US$10m | US$634k | -US$108m |
Compensación vs. Mercado: La compensación total de Garo($USD1.35M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD627.03K).
Compensación vs. Ingresos: La compensación de Garo ha sido consistente con los resultados de la empresa en el último año.
CEO
Garo Armen (72 yo)
Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994 and serves as its Interim Chief Financial Officer & Principal Financial Officer since January 8, 2026. H...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 32.3yrs | US$1.35m | 0.96% $ 1.2m | |
| Chief Medical Officer | 5.3yrs | US$902.82k | 0.14% $ 177.6k | |
| Director and President & CEO of MiNK Therapeutics | 4.3yrs | sin datos | 0.048% $ 61.4k | |
| Senior Director | less than a year | sin datos | 0.022% $ 28.3k | |
| Chief Information Officer | 4.3yrs | sin datos | sin datos | |
| Vice President of Investor Relations & Corporate Development | 1.5yrs | sin datos | sin datos | |
| Chief Communications & Government Relations Officer | 1.3yrs | sin datos | sin datos | |
| Chief People Officer | 4.3yrs | sin datos | sin datos | |
| Member of Advisory Board & Chief Strategic Advisor | 2.5yrs | sin datos | sin datos | |
| Chief Commercial Officer | 2.8yrs | sin datos | sin datos | |
| Head of Medical Affairs | less than a year | sin datos | sin datos | |
| Scientist II | no data | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de AGEN se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 27.3yrs | US$1.35m | 0.96% $ 1.2m | |
| Director and President & CEO of MiNK Therapeutics | 1.9yrs | sin datos | 0.048% $ 61.4k | |
| Member of Advisory Board & Chief Strategic Advisor | 3.3yrs | sin datos | sin datos | |
| Independent Director | 1.8yrs | US$175.04k | 0.094% $ 121.3k | |
| Member of Advisory Board | 3.3yrs | US$1.04m | sin datos | |
| Member of Advisory Board | 1.3yrs | US$204.37k | sin datos | |
| Independent Lead Director | 19.4yrs | US$199.45k | 0.0067% $ 8.6k | |
| Member of Advisory Board | 3.3yrs | sin datos | sin datos | |
| Independent Director | 19.2yrs | US$375.32k | 0.011% $ 14.3k | |
| Independent Director | 5.6yrs | US$150.04k | 0.014% $ 18.5k |
Junta con experiencia: La junta directiva de AGEN se considera experimentada (3.3 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 17:54 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Agenus Inc. está cubierta por 7 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |